Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cartesian Therapeutics Inc's Business Segments
Cartesian Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Operating
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Operating100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Operating | $ 0 | 100% |
Description of Cartesian Therapeutics Inc
Cartesian Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. The companys primary focus lies in the fields of advanced genetic medicine and engineered cell therapies. Below is an extensive description of the various segments, products, and services offered by Cartesian Therapeutics:
Segments:
1. Gene Therapy:
- Cartesian Therapeutics specializes in gene therapy solutions aimed at addressing genetic disorders. Their approach often involves the use of viral vectors to deliver therapeutic genes to target cells, promoting the expression of beneficial proteins that can correct genetic deficiencies.
2. Cell Therapy:
- The company is engaged in developing engineered cell therapies. This segment leverages the body’s immune cells, modifying them to enhance their ability to fight diseases — particularly cancer.
3. Biopharmaceuticals:
- Cartesian Therapeutics develops biopharmaceutical products derived from biological sources. These products include monoclonal antibodies, proteins, and nucleic acids, tailored for specific therapeutic indications.
4. Oncology:
- A significant focus within Cartesian involves oncology, where they explore therapies that can either enhance the immune response against tumors or directly target cancer cells through engineered biology.
Products:
1. Product Candidates:
- Autologous and Allogeneic CAR-T Therapies: Cartesian develops Chimeric Antigen Receptor (CAR) T-cell therapies, which are tailored to attack specific tumor antigens. These products are instrumental in the treatment of hematological malignancies and solid tumors.
- Neurodegenerative Disease Treatments: The company is researching gene therapies aimed at neurodegenerative diseases, utilizing innovative delivery systems to target diseased cells effectively.
2. RNA Therapeutics:
- The company is advancing RNA-based interventions, which leverage messenger RNA (mRNA), small interfering RNA (siRNA), or other RNA species to regulate gene expression in diseased states.
3. Biologics Development:
- Cartesian Therapeutics has ongoing projects involving the development of biologic drugs, including monoclonal antibodies that can modulate immune responses or inhibit disease pathways.
Services:
1. Research and Development:
- Cartesian Therapeutics invests heavily in R&D to discover and develop new therapeutic candidates. Their R&D services encompass preclinical development, clinical trials, and translational medicine services aimed at moving potential therapies from the lab to the clinic.
2. Collaborative Development:
- The company collaborates with various institutions and industry partners to develop and commercialize therapies. These partnerships can involve co-development agreements, licensing arrangements, and shared research initiatives.
3. Clinical Trial Management:
- Cartesian provides services related to the management and execution of clinical trials, including site selection, trial design, regulatory strategy, and patient recruitment.
4. Regulatory Affairs:
- An essential part of Cartesian’s offerings includes navigating the regulatory landscape. Their expertise in regulatory affairs helps ensure that their products meet the necessary legal and safety standards for market approval.
5. Manufacturing and CMC (Chemistry, Manufacturing, and Controls):
- The company has in-house capabilities and partnerships for the production of its therapeutic candidates. They focus on scalable manufacturing processes essential for clinical and commercial-scale production.
Conclusion:
Cartesian Therapeutics Inc. is emerging as a leader in the biopharmaceutical space, particularly in the development of genetic and engineered therapies. Their focus on innovative research, robust product development pipelines, and comprehensive service offerings positions them to address complex medical challenges effectively and transform patient care in critical therapeutic areas.
Segments:
1. Gene Therapy:
- Cartesian Therapeutics specializes in gene therapy solutions aimed at addressing genetic disorders. Their approach often involves the use of viral vectors to deliver therapeutic genes to target cells, promoting the expression of beneficial proteins that can correct genetic deficiencies.
2. Cell Therapy:
- The company is engaged in developing engineered cell therapies. This segment leverages the body’s immune cells, modifying them to enhance their ability to fight diseases — particularly cancer.
3. Biopharmaceuticals:
- Cartesian Therapeutics develops biopharmaceutical products derived from biological sources. These products include monoclonal antibodies, proteins, and nucleic acids, tailored for specific therapeutic indications.
4. Oncology:
- A significant focus within Cartesian involves oncology, where they explore therapies that can either enhance the immune response against tumors or directly target cancer cells through engineered biology.
Products:
1. Product Candidates:
- Autologous and Allogeneic CAR-T Therapies: Cartesian develops Chimeric Antigen Receptor (CAR) T-cell therapies, which are tailored to attack specific tumor antigens. These products are instrumental in the treatment of hematological malignancies and solid tumors.
- Neurodegenerative Disease Treatments: The company is researching gene therapies aimed at neurodegenerative diseases, utilizing innovative delivery systems to target diseased cells effectively.
2. RNA Therapeutics:
- The company is advancing RNA-based interventions, which leverage messenger RNA (mRNA), small interfering RNA (siRNA), or other RNA species to regulate gene expression in diseased states.
3. Biologics Development:
- Cartesian Therapeutics has ongoing projects involving the development of biologic drugs, including monoclonal antibodies that can modulate immune responses or inhibit disease pathways.
Services:
1. Research and Development:
- Cartesian Therapeutics invests heavily in R&D to discover and develop new therapeutic candidates. Their R&D services encompass preclinical development, clinical trials, and translational medicine services aimed at moving potential therapies from the lab to the clinic.
2. Collaborative Development:
- The company collaborates with various institutions and industry partners to develop and commercialize therapies. These partnerships can involve co-development agreements, licensing arrangements, and shared research initiatives.
3. Clinical Trial Management:
- Cartesian provides services related to the management and execution of clinical trials, including site selection, trial design, regulatory strategy, and patient recruitment.
4. Regulatory Affairs:
- An essential part of Cartesian’s offerings includes navigating the regulatory landscape. Their expertise in regulatory affairs helps ensure that their products meet the necessary legal and safety standards for market approval.
5. Manufacturing and CMC (Chemistry, Manufacturing, and Controls):
- The company has in-house capabilities and partnerships for the production of its therapeutic candidates. They focus on scalable manufacturing processes essential for clinical and commercial-scale production.
Conclusion:
Cartesian Therapeutics Inc. is emerging as a leader in the biopharmaceutical space, particularly in the development of genetic and engineered therapies. Their focus on innovative research, robust product development pipelines, and comprehensive service offerings positions them to address complex medical challenges effectively and transform patient care in critical therapeutic areas.